The addition of a CDK4/6 inhibitor to endocrine therapy prolonged progression-free survival (PFS) and overall survival (OS) in patients with advanced or metastatic HR+/HER2– breast cancer [8,9,10,11]. This evidence concerns the gene ERBB2 and breast carcinoma.